Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
This study is for people with haemophilia A, a condition where blood doesn't clot properly. The main goal is to check if a new medicine called efanesoctocog alfa can help improve joint swelling. Participants will take this medicine once a week for about a year. Researchers want to see if the swelling (called synovial hypertrophy) in joints gets better over these 12 months. This is an important step to understand how this new treatment might help people manage their haemophilia A and improve their joint health.
Auf einen Blick
Worum geht es in dieser Studie?
Imagine your body has tiny workers called clotting factors that help stop bleeding. In people with haemophilia A, there aren't enough of these workers (specifically, Factor VIII), which means they can bleed more easily and for longer. This bleeding often happens into joints, especially if they're not protected enough. Over time, this can cause the lining of the joints (called the synovium) to become thick and swollen, a condition known as synovial hypertrophy, which can lead to pain and damage.
This study, called a Phase 4 trial, is looking at a medicine named efanesoctocog alfa. If you have haemophilia A, you might already take medicine regularly to prevent bleeds – this is called prophylaxis. The study wants to see if using efanesoctocog alfa once a week can reduce the swelling in joints that are already affected by synovial hypertrophy. It's like checking if a new approach can help calm down irritated joints.
The main aim is to understand how well this treatment works over a year to make joints feel and look better. This kind of research helps doctors find new and better ways to manage haemophilia A, aiming to improve the quality of life for people living with the condition.
Wichtige Erkenntnisse
- This study evaluates efanesoctocog alfa for haemophilia A.
- It aims to reduce joint swelling (synovial hypertrophy).
- Treatment is once per week for around 12 months.
- Participants must have existing joint swelling and moderate to severe haemophilia A.
- The study helps improve understanding of new haemophilia treatments.
Wer könnte berechtigt sein?
To join this study, you need to have moderate to severe haemophilia A, meaning your natural Factor VIII levels are 5% or less. You also need to be at least 12 years old. A key part of joining is having at least one joint with some existing swelling (synovial hypertrophy), which will be checked using a special ultrasound.
It's important that you haven't had any major joint surgery on the affected joint in the last three months, and you shouldn't have any planned during the study. You should also have been taking regular preventative haemophilia medicine (prophylaxis) in the past year. Women who could become pregnant will need to use effective birth control during the study.
There are also reasons why you might not be able to join. For example, if you have other bleeding disorders besides haemophilia A, or if you are already taking part in another study that might affect this one, you wouldn't be eligible. The study team will go through all the details to make sure it's the right fit for you.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Do you have moderate to severe haemophilia A?
- Sind Sie 12 Jahre alt oder älter?
- Do you have at least one joint with existing swelling (synovial hypertrophy) that has been checked by a doctor?
- Have you been having regular preventative haemophilia medicine (prophylaxis) in the last year?
- Have you *not* had major joint surgery on the affected joint in the last 3 months, and don't have one planned soon?
Was beinhaltet die Teilnahme?
If you decide to take part, the study will last for about 12 months. Throughout this time, you will receive the study medicine, efanesoctocog alfa, once a week. The study team will regularly check how your joints are doing, especially the ones with swelling, using methods like ultrasound scans. They will also monitor your overall health and how you respond to the treatment. You will have regular visits to the clinic for these checks, and the team will explain everything in detail, including how to take the medicine and what to expect.
Potenzielle Risiken und Vorteile
Standorte (13)
- Orthopedic Institute for Children- Site Number : 8400009Verifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Rekrutierung
- Innovative Hematology, Inc.- Site Number : 8400006Verifizierte PostleitzahlIndianapolis, Vereinigte Staaten· Rekrutierung
- University of Iowa- Site Number : 8400004Verifizierte PostleitzahlIowa City, Vereinigte Staaten· Rekrutierung
- Ohio State University Hospital East- Site Number : 8400001Verifizierte PostleitzahlColumbus, Vereinigte Staaten· Rekrutierung
- Investigational Site Number : 1240003Verifizierte PostleitzahlHamilton, Kanada· Rekrutierung
- Investigational Site Number : 1240004Verifizierte PostleitzahlHamilton, Kanada· Rekrutierung
- Investigational Site Number : 3920003Verifizierte PostleitzahlKawasaki, Japan· Rekrutierung
- Investigational Site Number : 3920002Verifizierte PostleitzahlHiroshima, Japan· Rekrutierung
- Investigational Site Number : 3920001Verifizierte PostleitzahlSaitama, Japan· Rekrutierung
- Investigational Site Number : 3920004Verifizierte PostleitzahlTokyo, Japan· Rekrutierung
- Investigational Site Number : 1580003Verifizierte PostleitzahlKaohsiung City, Taiwan· Rekrutierung
- Investigational Site Number : 1580001Verifizierte PostleitzahlTaichung, Taiwan· Rekrutierung
Häufige Fragen
Was ist Hämophilie A?
Haemophilia A is a genetic bleeding disorder where your blood doesn't clot properly due to a lack of a specific protein called Factor VIII.
What is synovial hypertrophy?
It's when the lining of your joints (the synovium) becomes thick and swollen, often due to repeated bleeding into the joint. This can cause pain and lead to long-term joint damage.
What is efanesoctocog alfa?
It's a new type of medicine designed to replace the missing Factor VIII in people with haemophilia A. This study is testing how well it helps with joint swelling.
How long will I take part in the study?
If you join, you will be part of the study for about 12 months, receiving the treatment once a week.
Kann ich die Studie verlassen, wenn ich meine Meinung ändere?
Yes, completely. Taking part is your choice, and you can withdraw from the study at any time without having to give a reason.
Wie Sie mehr erfahren können
Empfohlene E-Mail für Testtransparenz (Kostenlos für USA & Kanada)
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.